Protocols for making hepatocytes from embryonic stem cells
This disclosure provides a newly developed strategy and particular options for differentiating pluripotent stem cells into cells of the hepatocyte lineage. Many of the protocols are based on a strategy in which the cells are first differentiated into early germ layer cells, then into hepatocyte precursors, and then into mature cells. The cells obtained have morphological features and phenotypic markers characteristic of human adult hepatocytes. They also show evidence of cytochrome p450 enzyme activity, validating their utility for commercial applications such as drug screening, or use in the manufacture of medicaments and medical devices for clinical therapy.
1. A method of screening a compound for an effect on a hepatocyte lineage cell in cell culture, comprising:
a. contacting the cell culture with the compound; and
b. observing a change in morphology, marker phenotype or metabolic activity in the hepatocyte lineage cells in the cell culture and correlating the change in morphology, marker phenotype or metabolic activity with the compound,
wherein the cell culture comprises hepatocyte lineage cells that are the progeny of an in vitro cell culture comprising non-malignant primate pluripotent stem cells which express stage-specific embryonic antigen 3 (SSEA3), stage-specific embryonic antigen 4 (SSEA4), the antigen recognized by antibody Tra-1-60 (Tra-1-60) and the antigen recognized by antibody Tra-1-81 (Tra-1-81), and
wherein greater than 50% of the cells in the culture are positive for glycogen storage.
2. The method of claim 1 , wherein the compound is a drug.
3. The method of claim 2 , wherein the drug is metabolized by an enzyme expressed in a hepatocyte lineage cell.
4. The method of claim 2 , wherein the drug is metabolized by cytochrome p450 enzyme.
5. The method of claim 1 , wherein the compound promotes the maturation of the hepatocyte lineage cell to a mature hepatocyte.
6. The method of claim 1 , wherein the compound is a peptide.
7. The method of claim 1 , wherein the compound is an oligonucleotide.
8. The method of claim 1 , wherein the compound is a cytotoxin.
9. The method of claim 1 , wherein the compound has antiviral activity.
10. The method of claim 1 , wherein the primate pluripotent stem cells which express SSEA3, SSEA4, Tra-1-60 and Tra-1-81 are not genetically modified.
11. A method of screening a compound for an effect on a hepatocyte lineage cell in cell culture, comprising:
providing a first in vitro cell culture comprising non-malignant primate pluripotent stem cells which express stage-specific embryonic antigen 3 (SSEA3), stage-specific embryonic antigen 4 (SSEA4), the antigen recognized by antibody Tra-1-60 (Tra-1-60) and the antigen recognized by antibody Tra-1-81 (Tra-1-81);
differentiating hepatocyte lineage cells from the primate pluripotent stem cells which express SSEA3, SSEA4, Tra-1-60 and Tra-1-81 to provide a second in vitro cell culture comprising hepatocyte lineage cells, wherein greater than 50% of the cells in the second culture are positive for glycogen storage;
contacting the cell culture comprising hepatocyte lineage cells with the compound; and
observing a change in morphology, marker phenotype or metabolic activity in the hepatocyte lineage cells in the cell culture and correlating the change in morphology, marker phenotype or metabolic activity with the compound.
12. The method of claim 11 , wherein the compound is a drug.
13. The method of claim 12 , wherein the drug is metabolized by an enzyme expressed in a hepatocyte lineage cell.
14. The method of claim 12 , wherein the drug is metabolized by cytochrome p450 enzyme.
15. The method of claim 11 , wherein the compound promotes the maturation of the hepatocyte lineage cell to a mature hepatocyte.
16. The method of claim 11 , wherein the compound is a peptide.
17. The method of claim 11 , wherein the compound is an oligonucleotide.
18. The method of claim 11 , wherein the compound is a cytotoxin.
19. The method of claim 11 , wherein the compound has antiviral activity.
20. The method of claim 11 , wherein the primate pluripotent stem cells which express SSEA3, SSEA4, Tra-1-60 and Tra-1-81 are not genetically modified.